Charlie is a research leader with experience in multiple therapeutic areas and modalities and whose work has led to the clinical testing and approval of several medicines. He is currently CSO at Affinia Therapeutics, which is developing an investigational medicine for BAG3 dilated cardiomyopathy using a novel cardiotropic capsid, and a venture partner at Atlas where he is helping with company creation. Before joining Affinia, Charlie was CSO at Editas Medicine where his group used the CRISPR gene-editing platform to advance multiple molecules into clinical development. Previously, he was VP of genetically defined diseases and genomics at Bristol Myers Squibb, where his group built a pipeline of novel therapeutics focused on CNS and cardiovascular rare diseases. Before joining industry, Charlie held an academic position at Vanderbilt University School of Medicine. He earned a Ph.D. in biology and a B.S. in chemical engineering from Massachusetts Institute of Technology and completed postdoctoral studies at the Whitehead Institute.